TGTX
TG Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website gtherapeutics.com
- Employees(FY) 245
- ISIN US88322Q1085
Performance
-2.6%
1W
+17.71%
1M
+19.16%
3M
+46.36%
6M
-3.51%
YTD
-47.9%
1Y
Profile
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
Investment Analysis Report: TGTX
Overview
TG Therapeutics Inc. (TGTX) operates in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The company has a market capitalization of $2.09 billion. In this report, we will conduct a comprehensive analysis of TGTX's financial statements to evaluate its valuation, financial...
Technical Analysis of TGTX 2024-05-10
Overview:
In analyzing the technical indicators for TGTX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key factors, we aim to offer valuable insights and predictions for the upcoming days.
Trend Analysis:
...Recent News & Updates
- 2024-03-01 07:30
- 2024-02-29 18:30
- 2024-02-29 09:22
- 2024-02-28 22:24
Q4 2023 TG Therapeutics Inc Earnings Call(Thomson Reuters StreetEvents)
- 2024-02-28 20:22
- 2024-02-28 16:05
TG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares?(Investor's Business Daily)
- 2024-02-28 08:10
- 2024-02-28 07:21
TG Therapeutics: Q4 Earnings Snapshot(Associated Press Finance)
- 2024-02-28 07:00
- 2024-02-27 19:10
- 2024-02-27 18:52
- 2024-02-27 18:00
- 2024-02-27 07:30
- 2024-02-26 18:30
- 2024-02-26 07:00
- 2024-02-25 18:00
- 2024-02-23 07:30
- 2024-02-22 18:30
- 2024-02-21 05:43
- 2024-02-20 10:00
- 2024-02-20 07:30
- 2024-02-19 21:00
- 2024-02-19 18:30
- 2024-02-12 18:20
Precision receives payments from TG Therapeutics for azer-cel(Pharmaceutical-business-review)
- 2024-01-22 06:30
7 Exciting Stocks Poised for Explosive Growth in Key Sectors(InvestorPlace)
- 2024-01-10 16:09
TG Therapeutics Reverses Its 225% Winning Streak On Lackluster Guidance(Investor's Business Daily)
- 2024-01-10 07:00
- 2024-01-09 20:33
- 2024-01-09 18:00
- 2024-01-09 09:03